Fireside Chat with "Hardy" Kagimoto

Technology Development & Innovation Center is excited to host a fireside chat with Dr. Tadahisa "Hardy" Kagimoto, CEO of Healios. Dr. Kagimoto is keen to meet researchers and innovators at OIST for an informal chat over lunch. Hardy has an amazing amount of experience with developing research-based technologies, working with investors, navigating medical regulatory issues in the US and Japan and much more - he is happy to share this experience with anyone who wants to have a discussion.

If you are interested, please sign up below, we are limiting places to 15. Lunch will be provided, and you can indicate your dietary preference when you sign up (the form will close once the limit has been reached).

Sign up form here.

If you have any questions before the event, please contact felix.rehnberg@oist.jp.

Bio

Dr. Tadahisa “Hardy” Kagimoto, MD, is the Founder, Chairman and CEO of Healios K.K., a biotechnology company leading the development of stem cell derived regenerative therapies to treat major areas of unmet medical need, including solid tumors, ischemic stroke, and acute respiratory distress syndrome. Prior to founding Healios, Dr. Kagimoto founded and ran as President and CEO Aqumen Biopharmaceuticals K.K., a biotechnology company that developed the de facto standard adjuvant used in eye surgery on a worldwide basis. Prior to founding Aqumen, Dr. Kagimoto was a clinical ophthalmologist. Dr. Kagimoto graduated from Kyushu University School of Medicine, and he holds patents in the US, Europe, Japan and China.

Full bio here.

This event is sponsored by the Technology Development and Innovation Center.